Skip to main content
. Author manuscript; available in PMC: 2011 Oct 27.
Published in final edited form as: JAMA. 2010 Oct 27;304(16):1821–1830. doi: 10.1001/jama.2010.1543

Figure 3. Timing of Events for Cardiovascular Death, Myocardial Infarction, or Ischemic Stroke and Stent Thrombosis.

Figure 3

Among patients treated with clopidogrel, hazard ratios are reported for cardiovascular death, myocardial infarction, or ischemic stroke and for stent thrombosis among carriers of one or two CYP2C19 reduced-function alleles versus non-carriers. Diamonds with horizontal lines represent the hazard ratio and corresponding 95% confidence intervals across the different timepoints. Nine studies contributed to the endpoint of cardiovascular death, myocardial infarction, or stroke from 0 to 30 days, and six studies from 31 days to end of follow-up. Analogously, six studies contributed to the endpoint of stent thrombosis from 0 to 30 days, and three studies from 31 days to end of follow-up. The number of events and the number of individuals at risk for events is presented for each study. In the analysis, a patient could have had a non-fatal event during 0 to 30 days and a subsequent event after day 30.